HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Murphy, B. R. Articles by Prince, G. A. Search for Related Content PubMed PubMed Citation Articles by Murphy, B. R. Articles by Prince, G. A. Agricola Articles by Murphy, B. R. Articles by Prince, G. A.

Immunosuppression of the Antibody Response to Respiratory Syncytial Virus (RSV) by Pre-existing Serum Antibodies: Partial Prevention by Topical Infection of the Respiratory Tract with Vaccinia Virus-RSV Recombinants

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, U.S.A.

Immunization strategies to prevent respiratory syncytial virus (RSV) disease will involve immunization of infants less than 2 months of age who possess maternally derived RSV antibodies. Vaccinia-RSV recombinant viruses are useful tools for defining parameters important in immunization against RSV and also are being considered as live virus vaccines for use in humans. Previous studies demonstrated that passively acquired RSV antibodies can suppress the immune response and the protective efficacy of vaccinia-RSV recombinants administered by the intradermal route. The present study demonstrates that the suppressive effects of passively acquired antibody on immunity induced by intradermally administered vaccinia-RSV recombinants in cotton rats can be partially overcome by administration of the recombinants by the intranasal route.

Keywords: RSV, vaccinia virus, antibody-mediated immune suppression

Received 6 December 1988; accepted 20 April 1989.

This article has been cited by other articles:

				M. H. Skiadopoulos, S. Biacchesi, U. J. Buchholz, J. M. Riggs, S. R. Surman, E. Amaro-Carambot, J. M. McAuliffe, W. R. Elkins, M. St. Claire, P. L. Collins, et al. The Two Major Human Metapneumovirus Genetic Lineages Are Highly Related Antigenically, and the Fusion (F) Protein Is a Major Contributor to This Antigenic Relatedness J. Virol., July 1, 2004; 78(13): 6927 - 6937. [Abstract] [Full Text] [PDF]

				A. C. Schmidt, D. R. Wenzke, J. M. McAuliffe, M. St. Claire, W. R. Elkins, B. R. Murphy, and P. L. Collins Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone J. Virol., February 1, 2002; 76(3): 1089 - 1099. [Abstract] [Full Text] [PDF]

				J. Welter, J. Taylor, J. Tartaglia, E. Paoletti, and C. B. Stephensen Vaccination against Canine Distemper Virus Infection in Infant Ferrets with and without Maternal Antibody Protection, Using Recombinant Attenuated Poxvirus Vaccines J. Virol., July 15, 2000; 74(14): 6358 - 6367. [Abstract] [Full Text]